Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px
Employment/Membership › Details

Numab–Vasella D: board, 201910– non-executive Board Director former Novartis CEO + before Sandoz

 

Period Period 2019-10-01
Organisations Organisation Numab Therapeutics AG
  Group Numab (Group)
  Organisation 2 Novartis AG (NYSE: NVS)
  Group Novartis (Group)
Products Product therapeutic antibody
  Product 2 pharmaceutical
Person Person Vasella, Daniel (Novartis CEO 199612–201001 after 1/10 continues as Chairman)
     

Numab Therapeutics AG. (10/15/19). "Press Release: Numab Appoints Daniel Vasella to Board of Directors". Wädenswil (Zurich).

Numab Therapeutics AG today announced that effective October 1 it has appointed former Novartis CEO and Chairman Dr. Daniel Vasella to its Board of Directors.

Dr. David Urech, CEO of Numab, said: “We are delighted to welcome Daniel Vasella to our Board of Directors. At our current stage of development, we expect to greatly benefit from Daniel’s vast experience. As we advance our proprietary pipeline programs and expand our roster of pharma collaborations, his strategic advice will be invaluable, and we look forward to working closely with him to bring Numab to the next stage.”

Dr. Daniel Vasella, served as Chairman of Novartis AG, a leading global medicines company, from 1999 until 2013 and as Chief Executive Officer of Novartis AG from 1996 to January 2010. From 1992 to 1996, Dr. Vasella held the positions of Chief Executive Officer, Chief Operating Officer, Senior Vice President and Head of Worldwide Development and Head of Corporate Marketing at Sandoz Pharma Ltd. He also served at Sandoz Pharmaceuticals Corporation from 1988 to 1992. Dr. Vasella is currently working as a coach to senior executives. He is also a director of PepsiCo and American Express Company, and is a member of several non-profit organizations.


About Numab

Founded in 2011, Numab develops a proprietary pipeline of multi-specific biotherapeutics in immunooncology and immunology, and has partnerships with Eisai, CStone Pharmaceuticals, Ono Pharmaceutical, Kaken Pharmaceutical, and Tillotts Pharma. Numab’s plug-and-play multi-specifics platform allows for a highly rational and reproducible process that rapidly yields promising clinical candidates with new mechanisms of action, superior efficacy and a favorable safety profile. For further information, visit www.numab.com.


MEDIA CONTACTS

Numab Therapeutics AG
David Urech
Chief Executive Officer
d.urech@numab.com

Capricorn One
Hans Herklots, Managing Director
+41 79 598 7149
capricorn1@bluewin.ch

   
Record changed: 2019-10-17

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Numab (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group BIO-Europe 2019 Hamburg Germany BEU2019 650x80px




» top